



Expedited Partner Therapy: Reducing Health Care Costs and Creating Healthy Communities

What is Expedited Partner Therapy?

- Expedited partner therapy (EPT) is an option for treating the sexually transmitted diseases chlamydia and gonorrhea.
- Typically when a patient tests positive for these sexually transmitted diseases (STDs), they are treated with antibiotics by a clinician. Treatment of the patient's sexual partner(s) is crucial to preventing reinfection of the patient. Conventional methods of ensuring treatment of a patient's sexual partners include:
 1. Direct contact by the clinician with a patient's sexual partner(s);
 2. A patient encouraging his/her partner(s) to visit a clinician; or
 3. A patient providing the name(s) of his/her partner(s) to health workers to contact.¹
- EPT enables healthcare professionals to provide patients with either antibiotics or prescriptions for antibiotics to their sexual partner(s) without a visit by the partner(s) to a health care center.
- EPT's legal status is different in every state. To find out more about your particular state, please visit: www.cdc.gov/std/ept/legal.

Why Use EPT? It Works!

- Traditional sexual partner referral is both a resource and time intensive option for STD control, and is increasingly limited given the decreasing financial and personnel resources in public health programs.
- EPT allows a health care provider to get treatment to a low-income or uninsured individual without a costly office visit or unduly taxing public health department staff.
- EPT is recommended by the Centers for Disease Control and Prevention (CDC).²
- Patients diagnosed with gonorrhea or chlamydia who received EPT were:
 - More likely to report that all of their sexual partners were treated than those who were told to refer their partners for treatment;
 - Less likely to report having sex with an untreated partner; and
 - Less likely to be diagnosed with another infection at a follow-up visit.
- States issue clinical care guidelines specifying the types of patients and antibiotics best suited for EPT through laws and policies.
- EPT is more successful than traditional patient referral approaches in getting antibiotic treatment to sexual partners.²

EPT Success Stories

- In Washington state, currently over one-third of all heterosexuals with chlamydia or gonorrhea receive EPT for their partners, and over half of those using EPT are offered medication.
- In California, nearly half of physicians and nurse practitioners report using EPT. California's partner treatment rate with EPT is 80%-- the same partner treatment rate for those who agreed to bring their partners with them to the clinic.
- In 2001, California was the first state to authorize EPT and after over ten years of use, no adverse effects have been reported.

The Health Burden of Chlamydia and Gonorrhea

- Almost 1.3 million cases of chlamydia and almost 309,000 cases of gonorrhea were reported in the US in 2010.³
- Blacks are 8 times more likely to contract chlamydia compared to whites; Native Americans and Hispanics are 4.3 and 2.7 times more likely, respectively.³
- Blacks are 18.7 times more likely to contract gonorrhea than whites; Native Americans and Hispanics are 4.6 and 2.2 times more likely, respectively.³

EPT Saves States Money!

- An estimated \$850 million is spent annually treating chlamydia and gonorrhea.⁴ EPT can decrease these costs by reducing the spread of infections and reliance on public services to treat STDs.
- If left untreated, chlamydia and gonorrhea can progress to pelvic inflammatory disease (PID) in women, resulting in additional treatment costs of \$1,167 per case of PID.⁵ Both infections are also a common cause of infertility.^{6,7} Because EPT increases STD treatment rates,^{6,7} it may decrease the number of cases of chlamydia and gonorrhea that lead to infertility and PID.
- Both chlamydia and gonorrhea change the immune system and may increase a person's chances of contracting HIV if exposed to the virus.^{8,9} For every HIV infection that is prevented, an estimated \$355,000 is saved in the cost of providing lifetime HIV treatment, resulting in significant cost-savings for the health care system and state coffers.¹⁰ EPT may be an effective HIV prevention tool, and cost saver, because it reduces chlamydia and gonorrhea rates.

What Can State Policymakers Do?

EPT can be a challenging topic since each state has different medical practice laws. In some states, regulations by medical boards prohibit doctors from using EPT. In others, statutes may prevent the practice of EPT. As referred to previously, the CDC's EPT website (www.cdc.gov/std/ept/legal) can help legislators understand the legal landscape in their state. In addition, state policymakers can:

- Learn More – Talk to your state's STD director to discuss if EPT can be implemented in your state and the potential public health impact.
- Educate Others – Talk to other policymakers about how many people are infected with chlamydia and gonorrhea and the consequences of persistent infections.
- Talk to Us – The National Coalition of STD Directors and the Council of State Governments are ready to provide officials with information about EPT and its potential impact on STDs. Contact us at:
 - Burke Hays, State Policy Associate, at the National Coalition of STD Directors (StatePolicy@ncsddc.org 202-842-4660, www.ncsddc.org)
 - Debra Miller, Director of Health Policy, at the Council on State Governments (dmiller@csg.org or 859-244-8241, www.csg.org)

- The National Coalition of STD Directors (NCSDD) is a partnership of public health professionals dedicated to promoting sexual health through the prevention of STDs. NCSDD provides dynamic leadership that strengthens STD Programs by advocating for effective policies, strategies, and sufficient resources and by increasing awareness of their medical and social impact.
- The Council of State Governments is our nation's only organization serving all three branches of state government. CSG is a region-based forum that fosters the exchange of insights and ideas to help state officials shape public policy. This offers unparalleled regional, national and international opportunities to network, develop leaders, collaborate and create problem-solving partnerships.

1. Golden, Matthew R., et al. "Effects of Expedited Treatment of Sex Partners on Recurrence of Persistent Gonorrhea or Chlamydia Infections." *New England Journal of Medicine*. 2005; 352:7, 676-85.
2. Centers for Disease Control and Prevention. "Expedited Partner Therapy." Atlanta, GA: US Department of Health and Human Services. Access February 2, 2012 via: <http://www.cdc.gov/std/ept/>
3. Centers for Disease Control and Prevention. "2010 Sexually Transmitted Diseases Surveillance." Atlanta, GA: US Department of Health and Human Services. Access February 2, 2012 via: <http://www.cdc.gov/std/stats10/gonorrhea.htm>
4. Chesson, H.W.; Blandford, J.M.; Gift, T.L.; Tao, G.; Irwin, K.L. "The Estimated Direct Cost of STD Among American Youth, 2000." Abstract PO75. National STD Prevention Conference. Philadelphia, PA. March 8-11, 2004.
5. Rein, D.; Kassler, W.; Irwin, K., et al. "Direct Medical Cost of Pelvic Inflammatory Disease and Its Sequelae: Decreasing, But Still Substantial."
6. Centers for Disease Control and Prevention. "Gonorrhea – CDC Fact Sheet." Access on February 2, 2012 via: <http://www.cdc.gov/std/gonorrhea/STDFact-gonorrhea.htm>
7. Centers for Disease Control and Prevention. "Chlamydia – CDC Fact Sheet." Access on February 3, 2012 via: <http://www.cdc.gov/std/chlamydia/STDFact-Chlamydia.htm>
8. Wasserheit JN. 1992. Epidemiologic synergy: Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. *Sexually Transmitted Diseases* 9:61-77.
9. Fleming, DT & Wasserheit, JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. 1999; 75(1): 3-17.
10. Centers for Disease Control and Prevention. "HIV Prevention in the United States at a Critical Crossroads." Accessed on February 2, 2012 via: http://www.cdc.gov/hiv/resources/reports/hiv_prev_us.htm

Nothing contained in this material is intended to influence, support, or defeat any piece of pending or proposed legislation, appropriation, or regulation at any governmental level. This piece is intended for educational purposes only.